%0 Journal Article %T Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis %A Hailin Pang %A Helong Zhang %A Ning Zhang %A Xiaobo Gao %A Yi Jiang %J Archive of "Therapeutics and Clinical Risk Management". %D 2019 %R 10.2147/TCRM.S191022 %X Given the increasing use of immune checkpoint inhibitors (ICIs), a concomitant rise in adverse events is inevitable. In a recent Phase III trial of ICIs versus placebo, we found the staggering difference of incidence of fatal adverse events (FAEs). Hence, we should determine the risk of FAEs in ICIs %K treatment-related mortality %K immune mediated death %K immune mediated mortality %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385768/